Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
9,285
Active, not recruiting, any sponsor type
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting22,408
- Not yet recruiting9,484
- Completed134,382
9,285 trials
Showing 1 to 25, recently updated first.
- A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate CancerActive, not recruiting
Syncromune, Inc.Industry
NCT06533644 · 91 participants (planned) · Start May 29, 2025 · Primary completion Apr 14, 2028
Drug: SV-102 · For: Metastatic Castration-resistant Prostate Cancer
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 23 sites in all
- Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerActive, not recruiting
Olema Oncology, Inc.Industry
NCT05508906 · 190 participants (planned) · Start Aug 31, 2022 · Primary completion Dec 31, 2027
Drug: Palazestrant; Ribociclib and 3 more · For: Metastatic Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer and 2 more
Sites: Gilbert, Arizona; San Francisco, California; Aurora, Colorado · 16 sites in all
- Compassionate Use of Metreleptin in Previously Treated People With Generalized LipodystrophyPivotal-lookingActive, not recruiting
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT02262832 · 24 participants · Start Oct 9, 2014 · Primary completion Jul 31, 2027
Drug: Metreleptin · For: Lipodystrophy; Diabetes; Hyperlipidemia
Sites: Bethesda, Maryland
- A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid LeukemiaActive, not recruiting
Kyowa Kirin Co., Ltd.Industry
NCT07623616 · 6 participants (planned) · Start Apr 23, 2026 · Primary completion Mar 2027
Drug: ziftomenib · For: Acute Myeloid Leukemia (AML)
Sites: Chiba, Japan; Gifu, Japan; Hyōgo, Japan · 20 sites in all
- A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.Active, not recruiting
Shenzhen Fosun Kairos Biotechnology Co., Ltd.Industry
NCT07606937 · 12 participants (planned) · Start Apr 29, 2026 · Primary completion Nov 30, 2026
Drug: FKC876 injection · For: Relapsed/Refractory Large B-cell Lymphoma
Sites: Beijing, China; Guangzhou, China; Suzhou, China · 6 sites in all
- A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated AdultsActive, not recruiting
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT07536308 · 83 participants · Start May 26, 2026 · Primary completion Apr 29, 2027
Drug: OCU500 · For: COVID-19
Sites: Decatur, Georgia; Baltimore, Maryland; Boston, Massachusetts · 5 sites in all
- NeSST2: The Development of a Noninvasive Short Synacthen TestPivotal-lookingActive, not recruiting
Sheffield Children's NHS Foundation TrustAcademic, hospital or other
NCT03514589 · 182 participants · Start Oct 12, 2012 · Primary completion Sep 30, 2026
Drug: nasal Tetracosactide; IV tetracosactide · For: Adrenal Suppression
Sites: Sheffield, United Kingdom
- Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous SystemActive, not recruiting
OHSU Knight Cancer InstituteAcademic, hospital or other
NCT03270059 · 41 participants · Start Oct 6, 2017 · Primary completion Dec 15, 2027
Drug: Ferumoxytol; Gadolinium · For: Central Nervous System Neoplasm; Cranial Nerve Disorder; Metastatic Malignant Neoplasm in the Brain
Sites: Portland, Oregon
- Attachment Inhibitor Comparison in Heavily Treatment Experienced PatientsPivotal-lookingActive, not recruiting
ViiV HealthcareGSK (GSK)
NCT02362503 · 371 participants · Start Feb 23, 2015 · Primary completion Aug 18, 2016
Drug: BMS-663068 · For: HIV Infections
Sites: Los Angeles, California; Palm Springs, California; San Francisco, California · 139 sites in all
- Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation TherapyActive, not recruiting
Vanderbilt-Ingram Cancer CenterAcademic, hospital or other
NCT05996432 · 48 participants (planned) · Start May 17, 2023 · Primary completion Nov 30, 2026
Drug: 18F-fluoromisonidazole · For: Head and Neck Squamous Cell Carcinoma; Brain Metastases
Sites: Nashville, Tennessee
- Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell CarcinomaActive, not recruiting
UNC Lineberger Comprehensive Cancer CenterAcademic, hospital or other
NCT03174275 · 39 participants · Start Dec 19, 2017 · Primary completion Feb 2, 2022
Drug: Durvalumab; Carboplatin and 2 more · For: Carcinoma, Squamous Cell; Oral Cancer; Oropharynx Cancer and 3 more
Sites: Chapel Hill, North Carolina; Nashville, Tennessee
- "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"Active, not recruiting
Hope Biosciences Research FoundationIndustry
NCT06800404 · 10 participants · Start May 2, 2025 · Primary completion Jan 2027
Drug: Autologous HB-adMSCs · For: Relapsing Remitting Multiple Sclerosis (RRMS); Multiple Sclerosis
Sites: Sugar Land, Texas
- A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular RoutesActive, not recruiting
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT07221162 · 140 participants · Start Dec 5, 2025 · Primary completion Nov 24, 2026
Drug: Aluminum Hydroxide Suspension; Boost-2867 and 1 more · For: COVID-19
Sites: San Francisco, California; Baltimore, Maryland; St Louis, Missouri · 8 sites in all
- Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic AnemiaActive, not recruiting
Medical College of WisconsinAcademic, hospital or other
NCT06517641 · 60 participants (planned) · Start May 12, 2025 · Primary completion Aug 1, 2028
Drug: Haploidentical donor bone marrow transplant; Unrelated donor bone marrow transplant · For: Severe Aplastic Anemia
Sites: Birmingham, Alabama; Duarte, California; Los Angeles, California · 25 sites in all
- Pediatric Long-Term Follow-up and Rollover StudyActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT03975829 · 163 participants · Start Nov 4, 2019 · Primary completion Nov 24, 2026
Drug: dabrafenib; trametinib · For: Diffuse Astrocytoma; Anaplastic Astrocytoma; Astrocytoma and 20 more
Sites: Phoenix, Arizona; Washington D.C., District of Columbia; Miami, Florida · 54 sites in all
- A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' DiseaseActive, not recruiting
SanofiSanofi (SNY)
NCT06984627 · 33 participants · Start Sep 2, 2025 · Primary completion Feb 11, 2027
Drug: Rilzabrutinib dose 1; Rilzabrutinib dose 2 · For: Graves' Disease
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Calgary, Canada · 24 sites in all
- Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06456346 · 300 participants (planned) · Start Jul 16, 2024 · Primary completion Sep 28, 2027
Drug: Bomedemstat; Hydroxyurea and 2 more · For: Essential Thrombocythemia
Sites: Glendale, Arizona; Glendale, California; Palo Alto, California · 171 sites in all
- A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung CancerPivotal-lookingActive, not recruiting
Shanghai Henlius BiotechIndustry
NCT07253142 · 120 participants (planned) · Start Feb 5, 2026 · Primary completion Jun 18, 2027
Drug: HLX43 dose 1; HLX43 dose 2 · For: Non Small Cell Lung Cancer; Small Cell Lung Cancer
Sites: Hefei, China; Fu'zhou, China; Guangzhou, China · 10 sites in all
- A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal CancerPivotal-lookingActive, not recruiting
Seagen, a wholly owned subsidiary of PfizerPfizer (PFE)
NCT05253651 · 325 participants · Start Oct 24, 2022 · Primary completion Dec 31, 2027
Drug: tucatinib; trastuzumab and 6 more · For: Colorectal Neoplasms
Sites: Glendale, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 319 sites in all
- Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)Pivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT02319837 · 1,068 participants · Start Dec 17, 2014 · Primary completion Jan 31, 2023
Drug: Enzalutamide; Placebo (No longer applicable in Open Label study period) and 1 more · For: Hormone Sensitive Prostate Cancer; Prostate Cancer; Cancer of the Prostate
Sites: Birmingham, Alabama; Anchorage, Alaska; Tucson, Arizona · 255 sites in all
- Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerActive, not recruiting
Aulos Bioscience, Inc.Industry
NCT05267626 · 159 participants (planned) · Start Apr 4, 2022 · Primary completion Feb 28, 2027
Drug: AU-007; Aldesleukin and 2 more · For: Advanced Solid Tumor; Metastatic Cancer; Cutaneous Melanoma and 1 more
Sites: Miami, Florida; Grand Rapids, Michigan; Minneapolis, Minnesota · 17 sites in all
- A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)Active, not recruiting
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT05460533 · 30 participants · Start Jul 12, 2022 · Primary completion Jul 2027
Drug: Tisagenlecleucel · For: B-cell Acute Lymphoblastic Leukemia
Sites: Los Angeles, California; Stanford, California; Aurora, Colorado · 6 sites in all
- A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated DiseasesActive, not recruiting
Pierre Fabre MedicamentIndustry
NCT04554914 · 190 participants (planned) · Start Jul 14, 2021 · Primary completion Jun 2027
Drug: Tabelecleucel · For: Epstein-Barr Virus (EBV)-Associated Diseases; EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD); EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD) and 8 more
Sites: Los Angeles, California; Orange, California; Palo Alto, California · 40 sites in all
- Effects of NLS-133, a Potential Non-Hormonal "On-Demand" Male ContraceptiveActive, not recruiting
Next Life SciencesIndustry
NCT07393334 · 10 participants (planned) · Start Dec 2, 2025 · Primary completion Feb 2027
Drug: NLS-133; Placebo and 1 more · For: Male Contraception; Semen Volume; Sperm Motility
Sites: Seattle, Washington
- A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With HyperphosphatemiaPivotal-lookingActive, not recruiting
R1 TherapeuticsIndustry
NCT06712654 · 168 participants (planned) · Start Jun 1, 2026 · Primary completion Feb 28, 2027
Drug: AP306 75 mg BID; AP306 125 mg BID and 6 more · For: Hyperphosphatemia; Chronic Kidney Disease Requiring Chronic Dialysis; End Stage Renal Disease on Dialysis
Sites: Huntsville, Alabama; Chula Vista, California; Los Angeles, California · 31 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.